These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
359 related items for PubMed ID: 11181368
41. Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424. Pace J, Bertasso A, Georgopapadakou NH. Antimicrob Agents Chemother; 1991 May; 35(5):910-5. PubMed ID: 1649574 [Abstract] [Full Text] [Related]
42. Studies on anti-MRSA parenteral cephalosporins. IV. A novel water-soluble N-phosphono type prodrug for parental administration. Ishikawa T, Nakayama Y, Tomimoto M, Niwa SI, Kamiyama K, Hashiguchi S, Iizawa Y, Okonogi K, Miyake A. J Antibiot (Tokyo); 2001 Apr; 54(4):364-74. PubMed ID: 11426661 [Abstract] [Full Text] [Related]
43. Antibacterial and pharmacokinetic properties of M14659, a new injectable semisynthetic cephalosporin. Mochizuki H, Oikawa Y, Yamada H, Kusakabe S, Shiihara T, Murakami K, Kato K, Ishiguro J, Kosuzume H. J Antibiot (Tokyo); 1988 Mar; 41(3):377-91. PubMed ID: 3130365 [Abstract] [Full Text] [Related]
45. Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics. Jones RN, Barry AL. Rev Infect Dis; 1983 Mar; 5 Suppl 1():S108-26. PubMed ID: 6221381 [Abstract] [Full Text] [Related]
46. Antibacterial activity and penicillin-binding protein affinity of new cephalosporin derivatives in Staphylococcus aureus and Escherichia coli. Singh MP, Lee YI, Singh R, Micetich RG, Wilkinson BJ. J Antimicrob Chemother; 1991 Apr; 27(4):459-68. PubMed ID: 1856125 [Abstract] [Full Text] [Related]
47. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin. Mine Y, Watanabe Y, Sakamoto H, Hatano K, Kuno K, Higashi Y, Kamimura T, Matsumoto Y, Tawara S, Matsumoto F. J Antibiot (Tokyo); 1993 Jan; 46(1):71-87. PubMed ID: 8436562 [Abstract] [Full Text] [Related]
48. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. II. Stability to beta-lactamases and affinity for penicillin-binding proteins. Markus A, Klesel N, Wollmann T, Isert D, Limbert M, Schrinner E, Seibert G, Bauernfeind A, Jungwirth R, Wilhelm R. J Antibiot (Tokyo); 1992 Apr; 45(4):521-6. PubMed ID: 1592684 [Abstract] [Full Text] [Related]
49. Antibacterial properties of SCE-2787, a new cephem antibiotic. Nakao M, Noji Y, Iwahi T, Yamazaki T. J Antimicrob Chemother; 1992 May; 29(5):509-18. PubMed ID: 1624391 [Abstract] [Full Text] [Related]
50. Discovery of MC-02,331, a new cephalosporin exhibiting potent activity against methicillin-resistant Staphylococcus aureus. Hecker SJ, Cho IS, Glinka TW, Zhang ZJ, Price ME, Lee VJ, Christensen BG, Boggs A, Chamberland S, Malouin F, Parr TR, Annamalai T, Blais J, Bond EL, Case L, Chan C, Crase J, Frith R, Griffith D, Harford L, Liu N, Ludwikow M, Mathias K, Rea D, Williams R. J Antibiot (Tokyo); 1998 Aug; 51(8):722-34. PubMed ID: 9766464 [Abstract] [Full Text] [Related]
51. Review of the in vitro spectrum of activity of imipenem. Jones RN. Am J Med; 1985 Jun 07; 78(6A):22-32. PubMed ID: 3890537 [Abstract] [Full Text] [Related]
52. Terminology of Staphylococcus aureus strains showing decreased susceptibility to methicillin. Smith JM. J Antimicrob Chemother; 1992 Feb 07; 29(2):219-21. PubMed ID: 1506337 [No Abstract] [Full Text] [Related]
53. In vitro activity of cefodizime. Knothe H, Shah PM. Infection; 1992 Feb 07; 20 Suppl 1():S3-8. PubMed ID: 1526673 [Abstract] [Full Text] [Related]
54. In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Watanabe N, Katsu K, Moriyama M, Kitoh K. Antimicrob Agents Chemother; 1988 May 07; 32(5):693-701. PubMed ID: 3134847 [Abstract] [Full Text] [Related]
55. Activity of meropenem, against gram-positive bacteria. Kayser FH, Morenzoni G, Strässle A, Hadorn K. J Antimicrob Chemother; 1989 Sep 07; 24 Suppl A():101-12. PubMed ID: 2808202 [Abstract] [Full Text] [Related]
56. [A comparative study of antibacterial activity of ceftibuten, ceftazidime, cefuroxime and ampicillin against clinical isolates]. Ergova R, K'oleian E, Kharalambieva Ia, Mitov I, Docheva Iu. Vutr Boles; 2000 Sep 07; 32(1):13-7. PubMed ID: 11195191 [Abstract] [Full Text] [Related]
57. The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Que YA, Entenza JM, Francioli P, Moreillon P. J Infect Dis; 1998 Jan 07; 177(1):146-54. PubMed ID: 9419181 [Abstract] [Full Text] [Related]
58. In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents. Gootz T, Retsema J, Girard A, Hamanaka E, Anderson M, Sokolowski S. Antimicrob Agents Chemother; 1989 Aug 07; 33(8):1160-6. PubMed ID: 2679370 [Abstract] [Full Text] [Related]
59. CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Ida T, Tsushima M, Ishii T, Atsumi K, Tamura A. J Infect Chemother; 2002 Jun 07; 8(2):138-44. PubMed ID: 12111566 [Abstract] [Full Text] [Related]
60. Novel cephalosporin derivatives possessing a bicyclic heterocycle at the 3-position. Part I: Synthesis and biological activities of 3-(benzothiazol-2-yl)thiocephalosporin derivatives, CP0467 and related compounds. Tsushima M, Iwamatsu K, Tamura A, Shibahara S. Bioorg Med Chem; 1998 Jul 07; 6(7):1009-17. PubMed ID: 9730237 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]